Saturday 17 October 2026
Export LIMN’s income statement to Excel — free account
Liminatus Pharma Inc.
LIMN Healthcare Biotechnology
In the quarter to June 2026, EPS fell 717.0%, free cash flow grew 89.0% and total debt was flat, each against the same quarter a year earlier.
3.04
0.17
−5.30%
Follow LIMN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+6 more TTM periods Free account |
0.00% | 70.02% | 16,458.79% | 294.43% | |
| (599.20%) | (344.72%) | (268.39%) | (471.47%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
243.98% | 104.30% | 11,091.43% | (3,447.10%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(17.99) | (20.97) | (16.42) | (4.10) | |
Free Cash Flow |
(9.72) | (9.96) | (11.82) | (3.97) | |
| Other line items | |||||
Cash ROIC |
(1,864.37%) | 124.01% | (367.33%) | (83.46%) | |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(10.82) | (13.74) | (31.94) | (53.77) | |
Operating CF/Net income |
2.42 | 0.98 | 1.07 | 0.32 | |
Depreciation/Fixed assets |
0.00 | 0.15 | 0.20 | 0.19 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(17.99) | (20.97) | (16.42) | (4.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates